GH Research (NASDAQ:GHRS) Shares Gap Up Following Analyst Upgrade

GH Research PLC (NASDAQ:GHRS)’s stock price gapped up before the market opened on Monday after Canaccord Genuity Group raised their price target on the stock from $30.00 to $31.00. The stock had previously closed at $11.68, but opened at $12.30. Canaccord Genuity Group currently has a buy rating on the stock. GH Research shares last traded at $11.92, with a volume of 12,509 shares.

GHRS has been the subject of a number of other research reports. JMP Securities dropped their price target on GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Monday, March 4th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GHRS. PEAK6 Investments LLC grew its position in GH Research by 72.9% in the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after acquiring an additional 16,991 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of GH Research by 14.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after buying an additional 13,579 shares during the period. Barclays PLC boosted its stake in shares of GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after acquiring an additional 31,500 shares during the last quarter. Lynx1 Capital Management LP raised its holdings in shares of GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after acquiring an additional 133,804 shares during the period. Finally, RTW Investments LP lifted its holdings in shares of GH Research by 53.4% in the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after acquiring an additional 1,158,172 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Stock Performance

The firm’s 50 day moving average is $10.37 and its two-hundred day moving average is $8.01. The stock has a market capitalization of $608.21 million, a PE ratio of -18.85 and a beta of 0.80.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, analysts anticipate that GH Research PLC will post -0.96 EPS for the current year.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).